US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Zealand Pharma A/S

67.62

-1.6960-2.45%

Volume:252.00

Turnover:17.25K

Market Cap:4.80B

PE:-37.42

High:69.00

Open:69.00

Low:67.62

Close:69.32

Loading ...

Overview Company News Filings

Zealand Pharma conference call on February 20 at 2pm CET (8am ET) to present full year 2024 financial results

Zealand Pharma initiated with an Equal Weight at Morgan Stanley

High Growth Tech Stocks To Watch In February 2025

Simply Wall St.

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

Steven R. Smith, MD, joins Zealand Pharma as Senior Global Medical Advisor in Obesity

Zealand Pharma to present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13th

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

Zealand Pharma major shareholder announcement: The Capital Group Companies, Inc.

Hot obesity drug market will keep investors gripped next year

Jefferies Sticks to Its Buy Rating for Zealand Pharma (ZLDPF)

Ironwood jumps after FDA rejects Zealand short bowel syndrome drug application

Zealand Pharma says FDA issues CRL for glepaglutide NDA

U.S. Food and Drug Administration issues Complete Response Letter for the glepaglutide New Drug Application for the treatment of short bowel syndrome

Berenberg Bank Sticks to Their Buy Rating for Zealand Pharma (ZLDPF)

Exploring Top High Growth Tech Stocks For Potential Portfolio Enhancement

Simply Wall St.

Zealand Pharma announces first participant enrolled in Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ZLDPF/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ZLDPF","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ZLDPF\",,,,,undefined,":{"symbol":"ZLDPF","market":"US","secType":"STK","nameCN":"Zealand Pharma A/S","latestPrice":67.624,"timestamp":1748462400000,"preClose":69.32,"halted":0,"volume":252,"delay":15,"floatShares":60575983,"shares":70935412,"eps":-1.807241,"marketStatus":"Closed","change":-1.696,"latestTime":"05-28 16:00:00 EDT Delay","open":69,"high":69,"low":67.624,"amount":17252.699999999997,"amplitude":0.01985,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-1.807241,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1748505600000},"marketStatusCode":5,"adr":0,"adrRate":0,"exchange":"PINK LIMITED","adjPreClose":69.32,"volumeRatio":1.042184},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ZLDPF\",,,,,undefined,":{"symbol":"ZLDPF","floatShares":60575983,"roa":"-13.97%","roe":"-21.27%","lyrEps":-1.844231,"volumeRatio":1.042184,"shares":70935412,"dividePrice":0,"high":69,"amplitude":0.01985,"preClose":69.32,"low":67.624,"week52Low":57.97,"pbRate":"3.92","psRate":"585.23","week52High":141.742,"institutionHeld":0,"latestPrice":67.624,"eps":-1.807241,"divideRate":0,"volume":252,"delay":15,"ttmEps":-1.807241,"open":69,"prevYearClose":102.36,"prevWeekClose":62.3556,"prevMonthClose":72.28,"prevQuarterClose":75.6,"fiveDayClose":63.42,"twentyDayClose":66.94,"sixtyDayClose":83.902},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ZLDPF\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2511852203","title":"Zealand Pharma conference call on February 20 at 2pm CET (8am ET) to present full year 2024 financial results","url":"https://stock-news.laohu8.com/highlight/detail?id=2511852203","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511852203?lang=en_us&edition=fundamental","pubTime":"2025-02-14 00:00","pubTimestamp":1739462400,"startTime":"0","endTime":"0","summary":"Copenhagen, Denmark,February 13, 2025–Zealand Pharma A/S  , a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announces that it will host a conference call on February 20, 2025, at 2:00 pm CET  following the announcement of financial results for the full year of 2024.Participating in the call will be President and Chief Executive Officer, Adam Steensberg; Chief Financial Officer, Henriette Wennicke; Chief Medical Officer, David Kendall; and Chief Commercial Officer, Eric Cox. There will be a presentation followed by a Q&A session.Zealand Pharma A/S is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand Pharma have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. The company has development partnerships with a number of pharma companies as well as commercial partnerships","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/zealand-pharma-conference-call-february-160000236.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4590","BK4139","BK4561","BK4581","ET","BK4588","BK4585","BK4144","ZLDPF","CET"],"gpt_icon":0},{"id":"2510326032","title":"Zealand Pharma initiated with an Equal Weight at Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2510326032","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510326032?lang=en_us&edition=fundamental","pubTime":"2025-02-12 17:55","pubTimestamp":1739354106,"startTime":"0","endTime":"0","summary":"Morgan Stanley initiated coverage of Zealand Pharma (ZLDPF) with an Equal Weight rating and DKK 755 price target The company’s next major catalyst ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/zealand-pharma-initiated-with-an-equal-weight-at-morgan-stanley?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/zealand-pharma-initiated-with-an-equal-weight-at-morgan-stanley?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2111349929.HKD","IE00BZ1G4Q59.USD","LU0320765646.SGD","LU2089283258.USD","BK4585","IE00BKVL7J92.USD","LU0225283273.USD","LU0158827948.USD","LU0912757837.SGD","LU1720051108.HKD","LU1732800096.USD","LU0106831901.USD","LU2271345857.HKD","LU0795875086.SGD","LU1668664300.SGD","LU0795875169.SGD","LU0158827781.USD","LU2133065610.SGD","LU2347655156.SGD","BK4127","LU2357305700.SGD","ZLDPF","LU1989772923.USD","LU0106261372.USD","LU2028103732.USD","LU0006306889.USD","BK4516","BK4534","LU1989772840.SGD","LU2023251221.USD","BK4588","LU1732799900.SGD","LU1074936037.SGD","BK4504","LU1548497426.USD","LU1363072403.SGD","LU0098860793.USD","LU0314104364.USD","LU2089284900.SGD","BK4581","LU0267386448.USD","LU0971096721.USD","LU1720051017.SGD","BK4139","LU1162221912.USD"],"gpt_icon":0},{"id":"2509876097","title":"High Growth Tech Stocks To Watch In February 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2509876097","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509876097?lang=en_us&edition=fundamental","pubTime":"2025-02-07 15:02","pubTimestamp":1738911737,"startTime":"0","endTime":"0","summary":"As global markets navigate a landscape marked by mixed corporate earnings and competitive pressures in the AI sector, U.S. stocks have experienced volatility, with notable fluctuations in tech-heavy indices like the Nasdaq Composite. In this context, identifying high-growth tech stocks requires careful consideration of companies that can adapt to rapid technological advancements and maintain robust performance despite market uncertainties.Click here to see the full list of 1226 stocks from our High Growth Tech and AI Stocks screener.We're going to check out a few of the best picks from our screener tool.CPSE:ZEAL Earnings and Revenue Growth as at Feb 2025. Operations: Kylinsec Technology focuses on the development and supply of software products. The company operates within the technology sector, leveraging its expertise to generate revenue through its software offerings.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/high-growth-tech-stocks-watch-070217285.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ZLDPF","BK4139"],"gpt_icon":0},{"id":"2503458019","title":"Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons","url":"https://stock-news.laohu8.com/highlight/detail?id=2503458019","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503458019?lang=en_us&edition=fundamental","pubTime":"2025-01-14 00:00","pubTimestamp":1736784000,"startTime":"0","endTime":"0","summary":"Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons. Copenhagen, Denmark, January 13, 2025 – Zealand Pharma A/S   , a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has received information on transactions in Zealand's shares or related securities conducted by persons discharging managerial responsibilities and/or their closely associated persons and hereby publishes the information on such transactions.Zealand Pharma A/S   is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. The company has development partnerships with a number of pharma companies as well as commercial partnerships for its mark","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/transactions-zealand-pharma-shares-related-160000695.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","ZEAL","ZLDPF"],"gpt_icon":0},{"id":"2501781517","title":"Steven R. Smith, MD, joins Zealand Pharma as Senior Global Medical Advisor in Obesity","url":"https://stock-news.laohu8.com/highlight/detail?id=2501781517","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501781517?lang=en_us&edition=fundamental","pubTime":"2025-01-08 00:00","pubTimestamp":1736265600,"startTime":"0","endTime":"0","summary":"Copenhagen, Denmark,January 7, 2025 –Zealand Pharma A/S  , a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced that Steven R. Smith, MD, has joined Zealand Pharma as Senior Global Medical Advisor – Obesity, as of January 1, 2025. Steven will report to David Kendall, Chief Medical Officer, and will support Zealand’s obesity research and clinical development programs.“We are very excited to welcome Steven to our team here at Zealand,” said David Kendall, Chief Medical Officer, Zealand Pharma. “As a recognized global leader in obesity and metabolism research, Steven will play a central role across the research and development organization as we advance our innovative peptide-based assets for the treatment of obesity and related health conditions.”Zealand Pharma A/S   is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand have advance","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/steven-r-smith-md-joins-160000752.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ZLDPF","GMRE","BK4139","MD","BK4225","BK4196","BK4203"],"gpt_icon":0},{"id":"2501791251","title":"Zealand Pharma to present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13th","url":"https://stock-news.laohu8.com/highlight/detail?id=2501791251","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501791251?lang=en_us&edition=fundamental","pubTime":"2025-01-07 00:00","pubTimestamp":1736179200,"startTime":"0","endTime":"0","summary":"Copenhagen, Denmark,January 6, 2025–Zealand Pharma A/S , a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced that Chief Executive Officer, Adam Steensberg, will present an overview of the company at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA at 2:15 p.m. PT  on Monday, January 13, 2025.Zealand Pharma A/S   is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. The company has development partnerships with a number of pharma companies as well as commercial partnerships for its marketed products.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/zealand-pharma-present-43rd-annual-160000146.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4137","BK4139","HCSG","ZLDPF"],"gpt_icon":0},{"id":"2494102753","title":"Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons","url":"https://stock-news.laohu8.com/highlight/detail?id=2494102753","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2494102753?lang=en_us&edition=fundamental","pubTime":"2024-12-26 00:40","pubTimestamp":1735144800,"startTime":"0","endTime":"0","summary":"Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons. Copenhagen, Denmark, December 25, 2024 – Zealand Pharma A/S   , a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has received information on transactions in Zealand Pharma’s shares or related securities conducted by persons discharging managerial responsibilities and/or their closely associated persons and hereby publishes the information on such transactions.Zealand Pharma A/S   is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. The company has development and partnership agreements with a number of pharma companies as well as commercial par","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/cgyYMo5QPKpW7CjArtwXjQ--~B/aD0yNDQ7dz02MDY7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/76be332007740327e38ca6218ee6aa06","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/cgyYMo5QPKpW7CjArtwXjQ--~B/aD0yNDQ7dz02MDY7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/76be332007740327e38ca6218ee6aa06"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/transactions-zealand-pharma-shares-related-164000064.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","ZLDPF","ZEAL"],"gpt_icon":0},{"id":"2494539027","title":"Zealand Pharma major shareholder announcement: The Capital Group Companies, Inc.","url":"https://stock-news.laohu8.com/highlight/detail?id=2494539027","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2494539027?lang=en_us&edition=fundamental","pubTime":"2024-12-26 00:30","pubTimestamp":1735144200,"startTime":"0","endTime":"0","summary":"Copenhagen, Denmark, 25 December 2024–Zealand Pharma A/S   , a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, today reports receipt on 23 December 2024 of notification pursuant to Section 38 of the Danish Capital Markets Act from the following major shareholder:. As of 20 December 2024, The Capital Group Companies, Inc. held voting rights corresponding to 6.20% of the total voting rights in Zealand Pharma A/S. The Capital Group Companies notes that neither The Capital Group Companies nor any of its affiliates own shares of Zealand Pharma A/S for its own account. Rather, the shares reported in this major shareholder notification are owned by accounts under the discretionary investment management of one or more of the investment management companies described in the notification form attached.About Zealand Pharma A/S Zealand Pharma A/S   is a biotechnology company focused on the discovery and development of peptide-b","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/cgyYMo5QPKpW7CjArtwXjQ--~B/aD0yNDQ7dz02MDY7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/76be332007740327e38ca6218ee6aa06","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/cgyYMo5QPKpW7CjArtwXjQ--~B/aD0yNDQ7dz02MDY7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/76be332007740327e38ca6218ee6aa06"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/zealand-pharma-major-shareholder-announcement-163000074.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","ZLDPF"],"gpt_icon":0},{"id":"2493541237","title":"Hot obesity drug market will keep investors gripped next year","url":"https://stock-news.laohu8.com/highlight/detail?id=2493541237","media":"Bloomberg","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493541237?lang=en_us&edition=fundamental","pubTime":"2024-12-23 20:22","pubTimestamp":1734956524,"startTime":"0","endTime":"0","summary":" — Disappointing trial results for Novo Nordisk A/S’s  experimental obesity shot capped a volatile year for investors in drug developers vying for a piece of pharma’s hottest market.Novo shares are rebounding on Monday, but the Danish company has still lost about $70 billion in market capitalization this year. Rival Eli Lilly & Co.  , meanwhile, has added more than $170 billion to its market value amid huge demand for its Zepbound drug, while shares in smaller firms like Zealand Pharma A/S and Viking Therapeutics Inc. have soared as they made headway with their own obesity treatments.More clarity around potential winners and losers may emerge next year, and the stakes are high — Goldman Sachs Group Inc. has estimated that obesity drugs could be a $130 billion market by 2030.“Excitement will remain high,” said Chris Eccles, a portfolio manager at AXA Investment Managers, in an interview. Once there’s more clinical data for drugs currently in development, investors will be able to “cast ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/pisLa0q7c2r_0aZ_gwlxBw--~B/aD02NzU7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/bloomberg_markets_842/d6d8e08ee049366cd32f1c0ad2b087b7","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/pisLa0q7c2r_0aZ_gwlxBw--~B/aD02NzU7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/bloomberg_markets_842/d6d8e08ee049366cd32f1c0ad2b087b7"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/hot-obesity-drug-market-keep-122204367.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1127390331.HKD","LU1989771016.USD","ZLDPF","IE0009355771.USD","LU0943347566.SGD","LU1069344957.HKD","LU0256863811.USD","SG9999001440.SGD","VKTX","LU1023059063.AUD","NVO","LU2264538146.SGD","SG9999013999.USD","LU0471298777.SGD","LU2491050154.USD","LU1868837136.USD","LU1280957306.USD","LU2324357040.USD","LLY","BK4139","LU0061475181.USD","IE00BK4W5L77.USD","BK4566","LU0882574139.USD","LU0058720904.USD","LU2491049909.HKD","LU0354030438.USD","LU0466842654.USD","LU0122379950.USD","BK4516","IE00BK4W5M84.HKD","SG9999015945.SGD","LU0820561909.HKD","LU2361044949.HKD","SG9999001176.USD","AMGN","LU0096364046.USD","LU0417517546.SGD","LU0889565916.HKD","SG9999014880.SGD","LU2211815571.USD","LU0106261372.USD","LU1712237335.SGD","LU1868837300.USD","LU0320765992.SGD","SGXZ81514606.USD","LU0238689110.USD","IE00BFTCPJ56.SGD","LU2242652126.USD","HIMS","LU0320765059.SGD","IE00B4R5TH58.HKD"],"gpt_icon":1},{"id":"2493427079","title":"Jefferies Sticks to Its Buy Rating for Zealand Pharma (ZLDPF)","url":"https://stock-news.laohu8.com/highlight/detail?id=2493427079","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493427079?lang=en_us&edition=fundamental","pubTime":"2024-12-21 02:38","pubTimestamp":1734719938,"startTime":"0","endTime":"0","summary":"Jefferies analyst Lucy Codrington maintained a Buy rating on Zealand Pharma (ZLDPF – Research Report) today and set a price target of DKK1,100.00. ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/jefferies-sticks-to-its-buy-rating-for-zealand-pharma-zldpf?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/jefferies-sticks-to-its-buy-rating-for-zealand-pharma-zldpf?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ZLDPF"],"gpt_icon":0},{"id":"2493219284","title":"Ironwood jumps after FDA rejects Zealand short bowel syndrome drug application","url":"https://stock-news.laohu8.com/highlight/detail?id=2493219284","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493219284?lang=en_us&edition=fundamental","pubTime":"2024-12-21 01:15","pubTimestamp":1734714929,"startTime":"0","endTime":"0","summary":"Shares of Ironwood Pharmaceuticals (IRWD) are up $1.17, or 30%, to $5.06 after Zealand Pharma (ZLDPF) announced that the Food and Drug Administrati...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ironwood-jumps-after-fda-rejects-zealand-short-bowel-syndrome-drug-application?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ironwood-jumps-after-fda-rejects-zealand-short-bowel-syndrome-drug-application?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ZLDPF","IRWD"],"gpt_icon":0},{"id":"2492948523","title":"Zealand Pharma says FDA issues CRL for glepaglutide NDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2492948523","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492948523?lang=en_us&edition=fundamental","pubTime":"2024-12-20 04:05","pubTimestamp":1734638724,"startTime":"0","endTime":"0","summary":"Zealand Pharma (ZLDPF) announced that the U.S. Food and Drug Administration has issued a Complete Response Letter for the company’s New Drug Applic...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/zealand-pharma-says-fda-issues-crl-for-glepaglutide-nda?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/zealand-pharma-says-fda-issues-crl-for-glepaglutide-nda?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ZLDPF","BK4588","BK4530","CRL","LU0390134368.USD","BK4121","BK4139","BK4585"],"gpt_icon":0},{"id":"2492489920","title":"U.S. Food and Drug Administration issues Complete Response Letter for the glepaglutide New Drug Application for the treatment of short bowel syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2492489920","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492489920?lang=en_us&edition=fundamental","pubTime":"2024-12-20 03:58","pubTimestamp":1734638280,"startTime":"0","endTime":"0","summary":"U.S. Food and Drug Administration issues Complete Response Letter for the glepaglutide New Drug Application for the treatment of short bowel syndrome. The FDA concluded that Zealand Pharma’s application did not meet the full requirements for substantial evidence to establish the efficacy and safety of the to-be-marketed dose of glepaglutide.Zealand Pharma will continue the dialogue with the FDA to align on the path toward obtaining regulatory approval in the U.S.Zealand Pharma expects to proceed with its current plans for a European Marketing Authorization Application submission in 2025.Copenhagen, Denmark, December 19, 2024 – Zealand Pharma A/S   , a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced that the U.S. Food and Drug Administration  has issued a Complete Response Letter  for the company’s New Drug Application  for glepaglutide, a long-acting GLP-2 analog, under development for the treatment of adult patients","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/cgyYMo5QPKpW7CjArtwXjQ--~B/aD0yNDQ7dz02MDY7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/76be332007740327e38ca6218ee6aa06","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/cgyYMo5QPKpW7CjArtwXjQ--~B/aD0yNDQ7dz02MDY7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/76be332007740327e38ca6218ee6aa06"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/u-food-drug-administration-issues-195800394.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4121","CRL","BK4172","BK4530","BK4588","SBS","BK4139","LU0390134368.USD","ZLDPF","BK4585"],"gpt_icon":0},{"id":"2490885944","title":"Berenberg Bank Sticks to Their Buy Rating for Zealand Pharma (ZLDPF)","url":"https://stock-news.laohu8.com/highlight/detail?id=2490885944","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490885944?lang=en_us&edition=fundamental","pubTime":"2024-12-11 14:35","pubTimestamp":1733898913,"startTime":"0","endTime":"0","summary":"Berenberg Bank analyst Laura Hindley maintained a Buy rating on Zealand Pharma (ZLDPF – Research Report) yesterday and set a price target of DKK1,0...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/berenberg-bank-sticks-to-their-buy-rating-for-zealand-pharma-zldpf?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/berenberg-bank-sticks-to-their-buy-rating-for-zealand-pharma-zldpf?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ZLDPF"],"gpt_icon":0},{"id":"2490072235","title":"Exploring Top High Growth Tech Stocks For Potential Portfolio Enhancement","url":"https://stock-news.laohu8.com/highlight/detail?id=2490072235","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490072235?lang=en_us&edition=fundamental","pubTime":"2024-12-11 09:08","pubTimestamp":1733879323,"startTime":"0","endTime":"0","summary":"In recent weeks, global markets have experienced mixed performances with major U.S. indexes like the S&P 500 and Nasdaq Composite continuing to hit record highs, while smaller-cap indices such as the Russell 2000 saw declines after a period of outperformance. This divergence highlights the ongoing rally in growth stocks, particularly within sectors like information technology and consumer discretionary, which have shown significant gains amid varied economic indicators such as job growth rebounds and anticipated policy changes from central banks. In this context, identifying high-growth tech stocks that align with current market trends can potentially enhance a portfolio by capitalizing on sectors demonstrating robust performance despite broader market volatility.Click here to see the full list of 1293 stocks from our High Growth Tech and AI Stocks screener.Assess Zealand Pharma's past performance with our detailed historical performance reports.Overview: Saudi Research and Media Group","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/d3vISzLZXw94x30FKv9beA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/d3vISzLZXw94x30FKv9beA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/exploring-top-high-growth-tech-010843531.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ZLDPF","BK4139"],"gpt_icon":0},{"id":"2490901911","title":"Zealand Pharma announces first participant enrolled in Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity","url":"https://stock-news.laohu8.com/highlight/detail?id=2490901911","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490901911?lang=en_us&edition=fundamental","pubTime":"2024-12-10 22:00","pubTimestamp":1733839200,"startTime":"0","endTime":"0","summary":"Zealand Pharma announces first participant enrolled in Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity. Zealand Pharma announces that the first participant has been enrolled in the Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity.“The initiation of this large and comprehensive Phase 2b trial of petrelintide in people with overweight orobesitymarks an important milestone for Zealand. Backed by strong and compelling clinical data reported to date, we are highly encouraged by the potential of petrelintide to represent a best-in-class alternative to incretin-based therapies and a future foundational therapy for weight management,” said David Kendall, MD, Chief Medical Officer at Zealand Pharma. “We are expanding the development program for petrelintide and look forward to initiating the Phase 2b trial of petrelintide in people withoverweight or obesity with type 2 diabetes in the first half of 2025.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/cgyYMo5QPKpW7CjArtwXjQ--~B/aD0yNDQ7dz02MDY7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/76be332007740327e38ca6218ee6aa06","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/cgyYMo5QPKpW7CjArtwXjQ--~B/aD0yNDQ7dz02MDY7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/76be332007740327e38ca6218ee6aa06"],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/zealand-pharma-announces-first-participant-140000287.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ZLDPF"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":2,"totalSize":36,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ZLDPF\",params:#limit:5,,,undefined,":[{"date":"2024-05-16","symbol":"ZLDPF","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1715846400000,"name":null,"time":"Pre-Market","dateTimestamp":1715832000000,"actualEps":null},{"market":"US","date":"2022-11-10","symbol":"ZLDPF","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1668056400000,"reportTimeType":"pre","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ZLDPF\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ZLDPF\",market:\"US\",delay:false,,,undefined,":{}}}